The use of venetoclax (ABT-199) in the treatment of CLL

Peter Hillmen, MBChB, PhD from St. James’ University Hospital, Leeds, UK, provides an overview of venetoclax (ABT-199) for the treatment of chronic lymphocytic leukemia (CLL), as a single-agent and in combination with other therapies. Peter Hillmen discusses two studies presented at the American Society of Hematology (ASH) 2015 Annual Meeting. These clinical trials study the use of venetoclax with rituximab and venetoclax with obinutuzumab.